Key result
A cumulative daunorubicin dose greater than 75 mg/m2 significantly increased the risk of cardiac disorders in children undergoing chemotherapy for acute lymphoblastic leukemia (OR 1.553).
Why the study?
Anthracycline-associated cardiotoxicity is frequently observed in cancer survivors years after treatment, but is rare in patients actively receiving chemotherapy.
What is the incidence and what are the risk factors for cardiac disorders in children with acute lymphoblastic leukemia during anthracycline chemotherapy?
Population
171 children with ALL undergoing chemotherapy
Design
Single-centre retrospective observational study
Authors
Loading...
Cumulative daunorubicin dose may elevate pediatric cardiac risk; leaves open need for prospective dose-optimization trials.
Cohort (n=171)
No
What is the incidence and what are the risk factors for cardiac disorders in children with acute lymphoblastic leukemia during anthracycline chemotherapy?
Odds Ratio: 1.553 (95% CI 1.005–3.108)
Absolute Event Rate: 56.32% vs 29.76%
p-value: p=0.030
Subclinical cardiac disorders are highly prevalent in children undergoing anthracycline chemotherapy for ALL, emphasizing the importance of routine ECG and echocardiographic monitoring during treatment.
Yu et al. (2021) conducted a cohort in Childhood Acute Lymphoblastic Leukemia (n=171). Daunorubicin vs. Cumulative dose ≤75 mg/m2 was evaluated on Incidence of cardiac disorders (OR 1.553, 95% CI 1.005-3.108, p=0.030). A cumulative daunorubicin dose greater than 75 mg/m2 significantly increased the risk of cardiac disorders in children undergoing chemotherapy for acute lymphoblastic leukemia (OR 1.553).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: